However, CCND1 overexpression is frequently observed in approximately 50% of breast cancers, with around 15% resulting from gene amplification (15, , , –19), while others are driven by alternative signaling pathways such as phosphoinositide-3 kinase (PI3K) or through posttranscriptional regulation (2). Here, CCND1 is linked to breast carcinoma.